Fidelity SPDR Advertisement
Home > Boards > US Listed > Medical - Drugs >

Provectus Biopharmaceuticals Inc. (PVCT)

Add PVCT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Gulfbreeze, Ovidius, buccaneer1961
Search This Board:
Last Post: 10/31/2014 5:08:33 PM - Followers: 163 - Board type: Free - Posts Today: 3

This board acts as a portal for PVCT investors, and retains the right to refuse service to individuals not in compliance with reasonable, responsible, and intelligible posting practices.

PVCT on YouTube...

Letter from the CEO Craig Dee's

We are a group of dedicated and entrepreneurial scientists, working together for the past 10 years, engaged in developing breakthrough technologies for cancer and other serious diseases. Our primary goal at Provectus is to develop alternative treatments that are safer, more effective, less invasive and more economical than conventional therapies.

Our Provectus Pharmatech division develops ethical pharmaceuticals for oncology and dermatology. Looking first to oncology, our novel drugs are designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing systemic side effects. In particular, our focus is on melanoma, breast and liver cancers – among the most difficult cancers to treat using conventional methods. We are very excited about the Phase I clinical trials of Provecta™ that began in 2005 for melanoma and breast cancer, and we are expanding to include liver cancer patients soon.

Targeting abnormal or diseased cells is also the approach we use in designing proprietary treatments for dermatological diseases, in particular, chronic, severe cases of psoriasis, eczema and acne. We anticipate that Phase II clinical trials of our topical agent Xantryl™ for psoriasis and eczema will begin soon. In addition, certain skin cancers may be targeted and treated more safely and effectively using Xantryl™.

In addition to our core pharmaceutical work, Provectus has developed a number of intellectual properties and technologies in the areas of medical devices and biotechnologies. Rather than dilute the efforts of Pharmatech, we are actively pursuing licensure, co-development, spin-offs and joint ventures of these technologies via our divisions Provectus Devicetech and Provectus Biotech. Devicetech encompasses both cosmetic and therapeutic treatments, with key attention to developing laser-based products to treat melanoma. Biotech is concentrating on producing vaccines to prevent certain cancers and other serious diseases, as well as detecting new viruses that could be associated with the onset of such diseases.

Our fourth division, Pure-ific Corp., is prepped to be sold or spun off to further develop its over-the-counter products. We are introducing professional skincare products for disposable glove users, and novel retail products for personal hygiene. In addition, we will be introducing an OTC product for acne sufferers.

We are proud of our intellectual capital at Provectus. We hold 15 U.S. patents in the pharmaceutical, medical device and biotech fields, with 19 additional patent applications in the works.

Provectus is a significant, emerging player in the huge and growing pharmaceutical industry. We believe in our potential to improve health care worldwide, using breakthrough products that are easy to manufacture and license, and economical to use. We appreciate your interest in our company, and welcome your comments and questions.

Craig Dees, Ph.D., CEO
Provectus Pharmaceuticals

PVCT 6 months chart:

Technical analysis:

PVCT News:



PVCT insiders transactions:


Drug Delivery Technology magazine special feature article "Revisiting Intralesional Delivery of Cancer Treatment", by Provectus CEO Craig Dees, Ph.D., compares Provectus’ novel cancer drugs to current cancer treatments.

May 17, 2007
Professor Peter Hersey, M.D. comments on PV-10 and a patient's response
Professor Peter Hersey, M.D., a professor of oncology at the University of Newcastle and Medical and Research Director of the Newcastle Melanoma Unit, comments on PV-10 and a patient's response.

Video can be viewed here.

This 15-minute clip follows the progress of an 86-year-old man treated with the drug. Prior to his treatment, his melanoma was so unresponsive to the current standard of care, including numerous invasive operations and toxic chemotherapy, that he was given only months to live.

Video can be viewed here.
Contact Info

Telephone: +1 (865) 769-4011
Fax: +1 (865) 769-4013

Mailing Address:
Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Hwy
Knoxville, TN 37931 USA

Transfer Agent:
(i.e. stockholder records, transfer, change of address, etc.)
Atlas Stock Transfer
5899 South State Street, Suite # 24
Murray, UT 84107
Telephone: +1 (801) 266-7151
Fax: +1 (801) 262-0907

Investor Relations:
Joseph Kessler
The Investor Relations Group
11 Stone St., 3rd fl
New York, NY 10004
Telephone: 212-825-3210
Fax: 212-825-3229

Public Relations:
The Investor Relations Group
Janet Vasquez
Telephone: 212-825-3210

Investment Advisor:
Damon Testaverde
Network 1 Financial Securities
Telephone: +1 (800) 205-8031
Share Statistics
45.45 m
35.35 m

Non-Corp. Insider Hold'gs:
22.20% (as of 4/1/07)

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
PVCT News: Current Report Filing (8-k) 05/27/2014 03:45:39 PM
PVCT News: Current Report Filing (8-k) 05/23/2014 02:19:35 PM
PVCT News: Current Report Filing (8-k) 05/21/2014 03:32:59 PM
PVCT News: Amended Statement of Changes in Beneficial Ownership (4/a) 05/20/2014 05:20:44 PM
PVCT News: Statement of Changes in Beneficial Ownership (4) 05/20/2014 06:08:15 AM
News News Alert: Current Report Filing (8-k) 10/31/2014 06:31:39 AM
#3564  Sticky Note Provectus SEC Filings... Gulfbreeze 05/01/14 12:10:06 AM
#3563  Sticky Note PLEASE STICKY THIS INFORMATION laxerpro22 04/30/14 11:21:55 PM
#6765   Of Interest Re: Immunotherapy FortStCowboy 10/31/14 05:08:33 PM
#6764   New CTD robofat 10/31/14 10:41:25 AM
#6763   Provectus Biopharmaceuticals, Inc. to Hold Quarterly Conference Call Paulness 10/31/14 10:35:30 AM
#6762   CTD: A gateway into China? (October 30, 2014) FortStCowboy 10/30/14 09:39:28 PM
#6761   The Forbes effect graces $PVCT. Elections around the himotephe 10/30/14 08:59:38 PM
#6760   I said sometime ago that the stock would FortStCowboy 10/30/14 06:36:13 PM
#6759   .....85 cents held...and now this pop 123tom 10/30/14 02:32:23 PM
#6758   I don't get the crow reference...? KPS88 10/30/14 02:26:43 PM
#6757   Ok if I give this crow a proper burial? FortStCowboy 10/30/14 01:17:36 PM
#6756   Looking to get back in at .96 with snidely 10/30/14 10:37:32 AM
#6755   Forbes article today odessafile 10/30/14 09:06:15 AM
#6754   It could be that people are getting nervous. big orange 10/30/14 08:53:21 AM
#6753   Keep eye on the Blog vorlon1966 10/29/14 11:32:29 PM
#6752   Link no good. Try this one: tim779 10/29/14 07:59:39 PM
#6751   New Forbes article on PVCT robofat 10/29/14 07:27:32 PM
#6750   New Trust Intelligence Post FortStCowboy 10/29/14 04:34:41 PM
#6749   Visible movement now in the daily chart pattern.... 123tom 10/28/14 05:31:30 PM
#6748   NEWS -- Provectus’ Intralesional PV-10 Clinical Data Published Paulness 10/28/14 07:59:30 AM
#6747   Seasoning my crow but it has been a FortStCowboy 10/27/14 01:38:50 PM
#6746   Look at the volume. Too low to be one_would_believe 10/27/14 01:25:37 PM
#6745   was thinking the same thing 236T568 10/27/14 01:24:12 PM
#6744   What I wonder about is if the China Ovidius 10/27/14 01:20:37 PM
#6743   PVCT drops to .8528 236T568 10/27/14 01:01:49 PM
#6742   It will be interesting to compare this Statement FortStCowboy 10/27/14 01:30:50 AM
#6741   Not much guess work involved in SinoPharm's interest: FortStCowboy 10/26/14 08:46:07 PM
#6740   Yet another potential advantage of PV-10 in avoiding FortStCowboy 10/25/14 01:15:13 PM
#6739   New Connecting the Dots post: robofat 10/25/14 12:57:26 PM
#6738   Internet Auction FortStCowboy 10/25/14 01:09:34 AM
#6737   Go figure. Fidelity says .95. Even weirder is tim779 10/24/14 11:28:53 PM
#6736   NASDAQ showing PVCT @ .915 with NO after FortStCowboy 10/24/14 07:52:02 PM
#6735   123tom's friday PVCT update.... 123tom 10/24/14 02:19:35 PM
#6734   What's the possibility of de-listment since we continue snidely 10/24/14 01:55:06 PM
#6733   A watched pot never boils vorlon1966 10/24/14 11:19:47 AM
#6732   right on! buccaneer1961 10/24/14 02:05:57 AM
#6731   It must be a good cake;) Egy_Pharaoh 10/22/14 07:16:37 PM
#6730   I'm expecting it but won't bet my auntie's FortStCowboy 10/22/14 03:35:02 PM
#6729   I think we ll have awesome holidays Egy_Pharaoh 10/22/14 02:35:35 PM
#6728   Detection of Immune Cell Infiltration Into Melanomas Treated FortStCowboy 10/22/14 01:41:02 PM
#6727   Need an update from you Tom, it's been Riz1 10/22/14 01:12:34 PM
#6726   From the IMS bulletin: A phase Ib/II trial FortStCowboy 10/22/14 12:42:41 PM
#6725   pacific, thanks for the link. Nice hearing so Stuki 10/22/14 12:08:44 PM
#6724   As soon as I posted remarks about being Zooker 10/22/14 12:05:09 PM
#6723   Above $1, but seems to hit a "wall" Zooker 10/22/14 12:03:40 PM
#6722   Buying more also! robofat 10/22/14 10:03:12 AM
#6721   buying more! yaya88888888888 10/22/14 01:09:22 AM
#6720   Worth everyone's time to listen to comments of Zooker 10/21/14 06:36:12 PM
#6719   Thanks pnw1. There is, IMO, no small measure FortStCowboy 10/21/14 03:12:21 PM
#6718   You can bet you'd know, if there were. FortStCowboy 10/21/14 02:43:13 PM
#6717   Video confirms "combination" treatment a little more? pacificnorthwest1 10/21/14 02:39:05 PM
#6716   Nice find.. Thanks for the video cowboy. BTW GD72 10/21/14 01:20:57 PM